GalliProst - A PET diagnostic for the stratification of prostate cancer patients

Prostate cancer (PCa) is the most common cancer in men in the UK, accounting for 25% of all
new cancer cases, with around 110 men diagnosed with PCa every day in the UK in 2011
(approximately 40k/year), and is the second most common cause of cancer related deaths.
Currently, no commercial technology exists for the molecular imaging of PCa, however, there
are several agents currently under development. These agents require expensive equipment
which needs to be operated by a specialist, limiting their utility in healthcare institutions.
Theragnostics seek to develop - ‘GalliProst™’ - an in vivo Positron Emission Tomography
(PET) diagnostic for the stratification of PCa patients. GalliProst™ is a whole body imaging
diagnostic which offers a more accurate diagnosis of PCa without the complex & costly
attributes associated with current methods, which will widen the access to PCa imaging in
hospitals. The initial target market for GalliProst™ is the EU & North American markets.
Market entry is expected 2018.